Avoiding tolerance against prostatic antigens with subdominant peptide epitopes

Journal of Immunotherapy

Volumn 24, Issue 3, 2001, Pages 237-241

  Grossmann, Michael E ^a   Davila, Eduardo ^a   Celis, Esteban ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immunotherapy; Prostate cancer; SV40T; T lymphocytes; Tumor model

Indexed keywords

CD40 ANTIGEN; EPITOPE; FLT3 LIGAND; GLUTAMINYLGLYCYLISOLEUCYLASPARAGINYLASPARAGINYLLEUCYLASPARTYLASPARAGINYLLEU CINE; PROSTATE ANTIGEN; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIESIS; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATITIS; SPLEEN CELL; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, NEOPLASM; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; CPG ISLANDS; EPITOPES; IMMUNE TOLERANCE; IMMUNOTHERAPY; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034996564     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200105000-00007     Document Type: Article

References (20)

1. Gittes RF. Carcinoma of the prostate, N Engl J Med 1991;324:236.
2. Dawson NA, Vogelzang NJ. Prostate cancer. New York: Wiley-Liss: 1994.
3. Wingo PA, Landis S, Parker S, et al. Using cancer registry and vital statistics data to estimate the number of new cancer cases and deaths in the Unites States for the upcoming year. J Reg Management 1998;25:43-51.
4. Ries LAG, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistic Review, 1973-1996.
5. Cooper EH, Robinson MR, Whelam P. Ferro MA. Tumor markers in prostate cancer. Cancer 1992;70:225.
6. Myers RB, Grizzle WE. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996;30:153.
7. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Canc Res 1992;58:143-75.
8. Nabholz M, MacDonald HR. Cytolytic T lymphocytes. Annu Rev Immunol 1983;1:273-305.
9. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunol Today 1997;18:175-82.
10. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
11. Greenburg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-43.
12. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
13. Davila E, Celis E. Repeated administration of CpG containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000;165:539-47.
14. Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 1995;69:6665.
15. Ashihara E, Shimazaki C, Sudo Y, et al. FLT-3 ligand mobilizes hematopoietic primitive and committed progenitor cells into blood in mice. Eur J Haematol 1998;60:86-92.
16. Soldevila G, Terrence G, Flavell A. Breaking immunological ignorance to an antigenic peptide of simian virus 40 large T antigen. J Immunol 1995;155:5590.
17. Krieg AM. The role of CpG motifs in innate immunity. Cur Opin Immunol 2000;12:35-43.
18. Iho S, Yamamoto T, Takahashi T, Yamamoto S. Oligonucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on huamn NK and activated T cells to induce IFN-gamma production in vitro. J Immunol 1999;163:3642-52.
19. Liu HM, Newbrough SE, Bhatia SK, et al. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony stimulating factor. Blood 1998;92:3730-6.
20. Ito D, Ogasawara K, Iwabuchi K, et al. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol 2000;164:1230-5.